ES2168766T3 - Preparacion farmaceutica que incluye el propeptido vwf. - Google Patents

Preparacion farmaceutica que incluye el propeptido vwf.

Info

Publication number
ES2168766T3
ES2168766T3 ES98929378T ES98929378T ES2168766T3 ES 2168766 T3 ES2168766 T3 ES 2168766T3 ES 98929378 T ES98929378 T ES 98929378T ES 98929378 T ES98929378 T ES 98929378T ES 2168766 T3 ES2168766 T3 ES 2168766T3
Authority
ES
Spain
Prior art keywords
vwf
pharmaceutical preparation
preparation
producing
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98929378T
Other languages
English (en)
Inventor
Hans-Peter Schwarz
Katalin Varadi
Peter Turecek
Hendrik Coenraad Hemker
Suzette Lucette Beguin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2168766T3 publication Critical patent/ES2168766T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una preparación farmacéutica para el tratamiento de los trastornos de coagulación de la sangre que comprende una cantidad eficaz del propéptido vWF así como un procedimiento de producción de dicha preparación.
ES98929378T 1997-05-28 1998-05-26 Preparacion farmaceutica que incluye el propeptido vwf. Expired - Lifetime ES2168766T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation

Publications (1)

Publication Number Publication Date
ES2168766T3 true ES2168766T3 (es) 2002-06-16

Family

ID=3502803

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98929378T Expired - Lifetime ES2168766T3 (es) 1997-05-28 1998-05-26 Preparacion farmaceutica que incluye el propeptido vwf.

Country Status (10)

Country Link
US (2) US7005502B1 (es)
EP (1) EP0977584B1 (es)
JP (1) JP4335978B2 (es)
AT (2) AT405485B (es)
AU (1) AU744643B2 (es)
CA (1) CA2288737A1 (es)
DE (1) DE69802918T2 (es)
ES (1) ES2168766T3 (es)
NO (1) NO324064B1 (es)
WO (1) WO1998053848A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
US7033994B2 (en) 1999-12-24 2006-04-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
ES2434035T3 (es) 2004-12-27 2013-12-13 Baxter International Inc. Conjugados de polímero-factor von Willebrand
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
CN105816858A (zh) 2007-12-28 2016-08-03 巴克斯特国际公司 重组vwf配方
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
AU2009307648C1 (en) 2008-10-21 2016-12-08 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP3495488A1 (en) * 2008-10-27 2019-06-12 Baxalta GmbH Models of thrombotic thrombocytopenic purpura and methods of use thereof
BR112012003802B1 (pt) 2009-08-20 2022-10-25 Takeda Pharmaceutical Company Limited Método para remover um vírus sem envelope lipídico de uma solução
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
KR102104843B1 (ko) 2015-10-02 2020-04-28 에이에스엠엘 네델란즈 비.브이. 계측 방법 및 장치, 컴퓨터 프로그램 및 리소그래피 시스템
KR20200037251A (ko) 2017-07-07 2020-04-08 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료
JP7307047B2 (ja) 2017-07-07 2023-07-11 武田薬品工業株式会社 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
JP2021519280A (ja) 2018-03-21 2021-08-10 バクスアルタ インコーポレイテッド クロマトグラフィー法によるｖｗｆとｖｗｆプロペプチドの分離
KR20210134642A (ko) 2019-02-01 2021-11-10 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf (rvwf)를 이용한 예방 치료 방법
WO2021050718A1 (en) 2019-09-11 2021-03-18 Baxalta Incorporated Methods of treatment related to complexes of von willebrand factor and complement c1q
MX2022009492A (es) 2020-02-04 2022-11-09 Takeda Pharmaceuticals Co Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT350726B (de) 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT378005B (de) 1983-08-20 1985-06-10 Linde Ag Verfahren zum desoxidieren von metallschmelzen
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
EP0674531A1 (de) 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
AT402788B (de) 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) 1994-05-31 1995-12-19 Sumitomo Metal Ind Ltd 新規細胞接着活性ペプチド
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
AT404359B (de) 1996-04-29 1998-11-25 Immuno Ag Gereinigte multimerase
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404554B (de) 1996-04-29 1998-12-28 Immuno Ag Pharmazeutische präparation

Also Published As

Publication number Publication date
NO324064B1 (no) 2007-08-06
EP0977584B1 (en) 2001-12-12
ATA91797A (de) 1999-01-15
JP4335978B2 (ja) 2009-09-30
AU744643B2 (en) 2002-02-28
DE69802918D1 (de) 2002-01-24
JP2001527579A (ja) 2001-12-25
DE69802918T2 (de) 2003-04-10
ATE210455T1 (de) 2001-12-15
AU7915698A (en) 1998-12-30
US7557188B2 (en) 2009-07-07
WO1998053848A1 (en) 1998-12-03
US7005502B1 (en) 2006-02-28
NO995843L (no) 2000-01-27
US20060003921A1 (en) 2006-01-05
EP0977584A1 (en) 2000-02-09
AT405485B (de) 1999-08-25
NO995843D0 (no) 1999-11-29
CA2288737A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
DE69333607D1 (de) Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen
NO175620C (no) Fremgangsmåte for fremstilling av et antitumorvirksomt legemiddel
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
ATE92061T1 (de) Substituierte tetraline, chromane und verwandte verbindungen fuer die behandlung von asthma, arthritis und verwandte krankheiten.
DK261490D0 (da) New pharmaceutical compound
ATE239474T1 (de) Verwendung von levobupivacain
MX9401294A (es) Derivados de azolona sustituida
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
EA199800866A1 (ru) Способ снятия боли
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
DE69736180D1 (de) Behandlung von manischen erkrankungen
ES2113345T3 (es) Tratamiento de la disfuncion cardiaca con la ayuda de compuestos 15-ceto-prostaglandina.
EA199800535A1 (ru) Способ лечения боли
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ES2179908T3 (es) Acidos sacarosamonocarboxilicos acilados.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
ES2120573T3 (es) 24-epi-1-alfa-hidroxivitamina d2 para tratar la osteoporosis.
EA199800818A1 (ru) Способ лечения бессонницы

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 977584

Country of ref document: ES